Global Yellow Fever Vaccine Market By Clinical Trial (Pre-Clinical, Phase I Clinical Trial, Others); By Application (Kids, Adults); By End-User (Healthcare Facilities, Government Vaccination Campaigns, Research Facilities, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
Diseases have plagued our existence since time immemorial. Researchers have been trying to eradicate diseases caused by microorganisms, but the challenges for the same are enormous. Many of these diseases are transmitted through other animals, such as mosquitoes, bats, fleas, rodents, amongst others. Mosquito bites are responsible for a number of diseases like Zika virus, West Nile virus, dengue, malaria, yellow fever amongst others. Scientists are increasingly working on the development of stable vaccines that can help in the prevention, and treatment of these diseases. Complexities associated with vaccine manufacturing include studying the nature of the disease-causing organism, genetic mutations and side effects, amongst a few. Yellow fever has emerged as a cause of concern amongst government bodies in Africa and South America. The yellow fever virus is predominantly found in the subtropical and tropical regions in Africa, and South America, owing to which there is a rising need for yellow fever vaccine market.
Mosquito acts as the vector in the case of yellow fever, and it is spread to human beings through mosquito bites, especially the Aedes and Haemagogus species. The acquisition of the virus by these mosquitoes is done through sucking the blood of infected individuals or animals (mainly primates). The virus is then transferred to the next host during the biting process. The virus can be transmitted from one individual to the mosquito briefly before the onset of yellow fever symptoms, to around five days after the symptoms are shown. The infection period lasts for a duration of three to six days. Some of the common symptoms of yellow fever include chills, severe headache, vomiting and weakness, amongst others. However, a major hurdle in the case of yellow fever diagnosis is that majority of individuals do not show any symptoms, which makes it difficult to isolate and quarantine the affected individuals. Complete recovery from yellow fever is also possible. However, companies are increasingly working on the development of optimal yellow fever vaccine to prevent the spread of the virus. Yellow fever vaccine importance can also be attributed to the fact that there is no treatment or cure for yellow fever infection, which implies that prevention is best route for stopping the spread. The rising demand for preventing the spread of the yellow fever virus, especially in Africa, coupled with the government mandate for individuals travelling to yellow fever affected countries in Africa and South America to take the vaccine shot before travel, is a major reason for the growth of the global yellow fever vaccine market.
COVID-19 Impact:
The coronavirus pandemic has created additional health concern amongst the government bodies. The pandemic has affected the supply chain drastically, and companies are increasingly trying to provide the vaccines to the countries in Africa. The yellow fever vaccine market is growing in demand, especially in Africa, as government bodies are increasingly trying to prevent complications associated with the pandemic by vaccinating individuals as soon as possible. Individuals affected by yellow fever may recover within a few days, but their health will be further deteriorated if they come in contact with coronavirus as well. These factors are ensuring that the yellow fever vaccine is in high demand globally, even during the pandemic situation.
In terms of revenue, the global yellow fever vaccine market is growing at a CAGR of 8.92% over the forecast period (2021 – 2029). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Yellow Fever Vaccine Market Revenue & Forecast, (US$ Million), 2021 – 2029
Application Outlook
The yellow fever vaccine is being increasingly made available for children, due to the backing by agencies such as the UNICEF and WHO. The vaccine can be given to children who are atleast 9 months old. Immunization of children plays a vital role in preventing the spread of the virus, as they're prone to mosquito bites, especially while playing outdoors. The lack of awareness about the yellow fever amongst children further stresses the importance of vaccinating them at an early age. The revenue from yellow fever vaccination for kids is expected to show the highest growth during the forecast years in the global yellow fever vaccine market.
Region Outlook
Middle East and Africa market has numerous buyers, especially in the form of government health bodies. The Eliminate Yellow fever Epidemics (EYE) Strategy, which was launched in 2017, supports about 40 high risk countries in Africa, and the Americas, to prevent and treat cases of yellow fever. Vulnerable population who have a higher chance of coming in contact with the virus are being identified, and vaccines are being provided to them for free, or for a nominal rate. The key aspect of the partnership is to ensure that the yellow fever outbreak doesn't reach the pandemic status. The goal of this initiative is to protect more than 1 billion individuals from the virus by 2026. Furthermore, the campaign is being backed by the United Nations Children's Fund (UNICEF), and it ensures that children are getting vaccinated at a faster pace by facilitating the availability of vaccine in vulnerable areas in Africa. These factor are driving the demand of yellow fever vaccine market.
Competitive Landscape
The report provides both, qualitative and quantitative research of the global yellow fever vaccine market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of key players operating in the Global Yellow Fever Vaccine Market are:
- Bio-Manguinhos
- Central Research Institute Kasauli
- FSUE Chumakov
- iBio
- Institut Pasteur de Dakar
- Sanofi
- Other Market Participants
Global Yellow Fever Vaccine Market
By Clinical Trial
- Pre-Clinical
- Phase I Clinical Trial
- Others
By Application
- Kids
- Adults
By End-User
- Healthcare Facilities
- Government Vaccination Campaigns
- Research Facilities
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1.
Market
Segmentation
1.2.
Years
Considered
1.2.1.
Historic
Years: 2015 - 2019
1.2.2.
Base
Year: 2020
1.2.3.
Forecast
Years: 2021 – 2029
2.
Key
Target Audiences
3.
Research
Methodology
3.1.
Primary
Research
3.1.1.
Research
Questionnaire
3.1.2.
Global
Percentage Breakdown
3.1.3.
Primary
Interviews: Key Opinion Leaders (KOLs)
3.2.
Secondary
Research
3.2.1.
Paid
Databases
3.2.2.
Secondary
Sources
3.3.
Market
Size Estimates
3.3.1.
Top-Down
Approach
3.3.2.
Bottom-Up
Approach
3.4.
Data
Triangulation Methodology
3.5.
Research
Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Yellow Fever Vaccine Market
6.
Market
Synopsis: Yellow Fever Vaccine Market
7.
Yellow
Fever Vaccine Market Analysis: Qualitative Perspective
7.1.
Introduction
7.1.1.
Product
Definition
7.1.2.
Industry
Development
7.2.
Market
Dynamics
7.2.1.
Drivers
7.2.2.
Restraints
7.2.3.
Opportunities
7.2.4.
Challenges
7.3.
Trends
in Yellow Fever Vaccine Market
7.4.
Market
Determinants Radar Chart
7.5.
Macro-Economic
and Micro-Economic Indicators: Yellow Fever Vaccine Market
7.6.
Porter’s
Five Force Analysis
7.7.
Impact
of Covid-19 on Yellow Fever Vaccine Market
8.
Global
Yellow Fever Vaccine Market Analysis and Forecasts, 2021 – 2029
8.1.
Overview
8.1.1.
Global
Yellow Fever Vaccine Market Revenue (US$ Mn)
8.2.
Global
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Application
8.2.1.
Kids
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.1.3.
Market
Forecast, 2021 - 2029
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2020
8.2.1.5.1.2. Market Forecast, 2021 - 2029
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2020
8.2.1.5.2.2. Market Forecast, 2021 - 2029
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2020
8.2.1.5.3.2. Market Forecast, 2021 - 2029
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2020
8.2.1.5.4.2. Market Forecast, 2021 - 2029
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2020
8.2.1.5.5.2. Market Forecast, 2021 - 2029
8.2.2.
Adults
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.2.3.
Market
Forecast, 2021 - 2029
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2020
8.2.2.5.1.2. Market Forecast, 2021 - 2029
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2020
8.2.2.5.2.2. Market Forecast, 2021 - 2029
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2020
8.2.2.5.3.2. Market Forecast, 2021 - 2029
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2020
8.2.2.5.4.2. Market Forecast, 2021 - 2029
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2020
8.2.2.5.5.2. Market Forecast, 2021 - 2029
8.3.
Key
Segment for Channeling Investments
8.3.1.
By
Application
9.
Global
Yellow Fever Vaccine Market Analysis and Forecasts, 2021 – 2029
9.1.
Overview
9.2.
Global
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
9.2.1.
Healthcare
Facilities
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.1.3.
Market
Forecast, 2021 - 2029
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2020
9.2.1.5.1.2. Market Forecast, 2021 - 2029
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2020
9.2.1.5.2.2. Market Forecast, 2021 - 2029
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2020
9.2.1.5.3.2. Market Forecast, 2021 - 2029
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2020
9.2.1.5.4.2. Market Forecast, 2021 - 2029
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2020
9.2.1.5.5.2. Market Forecast, 2021 - 2029
9.2.2.
Government
Vaccination Campaigns
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.2.3.
Market
Forecast, 2021 - 2029
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2020
9.2.2.5.1.2. Market Forecast, 2021 - 2029
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2020
9.2.2.5.2.2. Market Forecast, 2021 - 2029
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2020
9.2.2.5.3.2. Market Forecast, 2021 - 2029
9.2.2.5.4.
Middle East
and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2020
9.2.2.5.4.2. Market Forecast, 2021 - 2029
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2020
9.2.2.5.5.2. Market Forecast, 2021 - 2029
9.2.3.
Research
Facilities
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.3.3.
Market
Forecast, 2021 - 2029
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1. Market Estimation, 2015 - 2020
9.2.3.5.1.2. Market Forecast, 2021 - 2029
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2020
9.2.3.5.2.2. Market Forecast, 2021 - 2029
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2020
9.2.3.5.3.2. Market Forecast, 2021 - 2029
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2020
9.2.3.5.4.2. Market Forecast, 2021 - 2029
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2020
9.2.3.5.5.2. Market Forecast, 2021 - 2029
9.2.4.
Others
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.4.3.
Market
Forecast, 2021 - 2029
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1.
North
America
9.2.4.5.1.1. Market Estimation, 2015 - 2020
9.2.4.5.1.2. Market Forecast, 2021 - 2029
9.2.4.5.2.
Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2020
9.2.4.5.2.2. Market Forecast, 2021 - 2029
9.2.4.5.3.
Asia
Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2020
9.2.4.5.3.2. Market Forecast, 2021 - 2029
9.2.4.5.4.
Middle
East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2020
9.2.4.5.4.2. Market Forecast, 2021 - 2029
9.2.4.5.5.
Latin
America
9.2.4.5.5.1. Market Estimation, 2015 - 2020
9.2.4.5.5.2. Market Forecast, 2021 - 2029
9.3.
Key
Segment for Channeling Investments
9.3.1.
By End-User
10. Global Yellow Fever Vaccine Market Analysis
and Forecasts, 2021 – 2029
10.1. Overview
10.2. Global Yellow Fever Vaccine Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
10.2.1. Pre-Clinical
10.2.1.1.
Definition
10.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
10.2.1.3.
Market Forecast,
2021 - 2029
10.2.1.4.
Compound
Annual Growth Rate (CAGR)
10.2.1.5.
Regional
Bifurcation
10.2.1.5.1.
North
America
10.2.1.5.1.1. Market Estimation, 2015 - 2020
10.2.1.5.1.2. Market Forecast, 2021 - 2029
10.2.1.5.2.
Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2020
10.2.1.5.2.2. Market Forecast, 2021 - 2029
10.2.1.5.3.
Asia
Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2020
10.2.1.5.3.2. Market Forecast, 2021 - 2029
10.2.1.5.4.
Middle
East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2020
10.2.1.5.4.2. Market Forecast, 2021 - 2029
10.2.1.5.5.
Latin
America
10.2.1.5.5.1. Market Estimation, 2015 - 2020
10.2.1.5.5.2. Market Forecast, 2021 - 2029
10.2.2. Phase I Clinical Trial
10.2.2.1.
Definition
10.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
10.2.2.3.
Market
Forecast, 2021 - 2029
10.2.2.4.
Compound
Annual Growth Rate (CAGR)
10.2.2.5.
Regional
Bifurcation
10.2.2.5.1.
North
America
10.2.2.5.1.1. Market Estimation, 2015 - 2020
10.2.2.5.1.2. Market Forecast, 2021 - 2029
10.2.2.5.2.
Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2020
10.2.2.5.2.2. Market Forecast, 2021 - 2029
10.2.2.5.3.
Asia
Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2020
10.2.2.5.3.2. Market Forecast, 2021 - 2029
10.2.2.5.4.
Middle
East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2020
10.2.2.5.4.2. Market Forecast, 2021 - 2029
10.2.2.5.5.
Latin
America
10.2.2.5.5.1. Market Estimation, 2015 - 2020
10.2.2.5.5.2. Market Forecast, 2021 - 2029
10.2.3. Others
10.2.3.1.
Definition
10.2.3.2.
Market
Estimation and Penetration, 2015 - 2020
10.2.3.3.
Market
Forecast, 2021 - 2029
10.2.3.4.
Compound
Annual Growth Rate (CAGR)
10.2.3.5.
Regional
Bifurcation
10.2.3.5.1.
North
America
10.2.3.5.1.1. Market Estimation, 2015 - 2020
10.2.3.5.1.2. Market Forecast, 2021 - 2029
10.2.3.5.2.
Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2020
10.2.3.5.2.2. Market Forecast, 2021 - 2029
10.2.3.5.3.
Asia
Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2020
10.2.3.5.3.2. Market Forecast, 2021 - 2029
10.2.3.5.4.
Middle
East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2020
10.2.3.5.4.2. Market Forecast, 2021 - 2029
10.2.3.5.5.
Latin
America
10.2.3.5.5.1. Market Estimation, 2015 - 2020
10.2.3.5.5.2. Market Forecast, 2021 - 2029
10.3. Key Segment for Channeling Investments
10.3.1. By Clinical Trial Phase
11. North America Yellow Fever Vaccine Market
Analysis and Forecasts, 2021 - 2029
11.1. Overview
11.1.1. North America Yellow Fever Vaccine Market
Revenue (US$ Mn)
11.2. North America Yellow Fever Vaccine Market
Revenue (US$ Mn) and Forecasts, By Application
11.2.1. Kids
11.2.2. Adults
11.3. North America Yellow Fever Vaccine Market
Revenue (US$ Mn) and Forecasts, By End-User
11.3.1. Healthcare Facilities
11.3.2. Government Vaccination Campaigns
11.3.3. Research Facilities
11.3.4. Others
11.4. North America Yellow Fever Vaccine Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
11.4.1. Pre-Clinical
11.4.2. Phase I Clinical Trial
11.4.3. Others
11.5. North America Yellow Fever Vaccine Market
Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1.
U.S
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Application
11.5.1.1.1.
Kids
11.5.1.1.2.
Adults
11.5.1.2.
U.S
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
11.5.1.2.1.
Healthcare
Facilities
11.5.1.2.2.
Government
Vaccination Campaigns
11.5.1.2.3.
Research
Facilities
11.5.1.2.4.
Others
11.5.1.3.
U.S
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phase
11.5.1.3.1.
Pre-Clinical
11.5.1.3.2.
Phase I
Clinical Trial
11.5.1.3.3.
Others
11.5.2. Canada
11.5.2.1.
Canada
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Application
11.5.2.1.1.
Kids
11.5.2.1.2.
Adults
11.5.2.2.
Canada
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
11.5.2.2.1.
Healthcare
Facilities
11.5.2.2.2.
Government
Vaccination Campaigns
11.5.2.2.3.
Research
Facilities
11.5.2.2.4.
Others
11.5.2.3.
Canada
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phase
11.5.2.3.1.
Pre-Clinical
11.5.2.3.2.
Phase I
Clinical Trial
11.5.2.3.3.
Others
11.5.3. Mexico
11.5.3.1.
Mexico
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Application
11.5.3.1.1.
Kids
11.5.3.1.2.
Adults
11.5.3.2.
Mexico
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
11.5.3.2.1.
Healthcare
Facilities
11.5.3.2.2.
Government
Vaccination Campaigns
11.5.3.2.3.
Research
Facilities
11.5.3.2.4.
Others
11.5.3.3.
Mexico
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phase
11.5.3.3.1.
Pre-Clinical
11.5.3.3.2.
Phase I
Clinical Trial
11.5.3.3.3.
Others
11.5.4. Rest of North America
11.5.4.1.
Rest of
North America Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By
Application
11.5.4.1.1.
Kids
11.5.4.1.2.
Adults
11.5.4.2.
Rest of
North America Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By
End-User
11.5.4.2.1.
Healthcare
Facilities
11.5.4.2.2.
Government
Vaccination Campaigns
11.5.4.2.3.
Research
Facilities
11.5.4.2.4.
Others
11.5.4.3.
Rest of
North America Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By
Clinical Trial Phase
11.5.4.3.1.
Pre-Clinical
11.5.4.3.2.
Phase I
Clinical Trial
11.5.4.3.3.
Others
11.6. Key Segment for Channeling Investments
11.6.1. By Country
11.6.2. By Application
11.6.3. By End-User
11.6.4. By Clinical Trial Phase
12. Europe Yellow Fever Vaccine Market Analysis
and Forecasts, 2021 - 2029
12.1. Overview
12.1.1. Europe Yellow Fever Vaccine Market Revenue
(US$ Mn)
12.2. Europe Yellow Fever Vaccine Market Revenue
(US$ Mn) and Forecasts, By Application
12.2.1. Kids
12.2.2. Adults
12.3. Europe Yellow Fever Vaccine Market Revenue
(US$ Mn) and Forecasts, By End-User
12.3.1. Healthcare Facilities
12.3.2. Government Vaccination Campaigns
12.3.3. Research Facilities
12.3.4. Others
12.4. Europe Yellow Fever Vaccine Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
12.4.1. Pre-Clinical
12.4.2. Phase I Clinical Trial
12.4.3. Others
12.5. Europe Yellow Fever Vaccine Market Revenue
(US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1.
France
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Application
12.5.1.1.1.
Kids
12.5.1.1.2.
Adults
12.5.1.2.
France
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.1.2.1.
Healthcare
Facilities
12.5.1.2.2.
Government
Vaccination Campaigns
12.5.1.2.3.
Research
Facilities
12.5.1.2.4.
Others
12.5.1.3.
France
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phase
12.5.1.3.1.
Pre-Clinical
12.5.1.3.2.
Phase I
Clinical Trial
12.5.1.3.3.
Others
12.5.2. The UK
12.5.2.1.
The UK
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Application
12.5.2.1.1.
Kids
12.5.2.1.2.
Adults
12.5.2.2.
The UK
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.2.2.1.
Healthcare
Facilities
12.5.2.2.2.
Government
Vaccination Campaigns
12.5.2.2.3.
Research
Facilities
12.5.2.2.4.
Others
12.5.2.3.
The UK
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phase
12.5.2.3.1.
Pre-Clinical
12.5.2.3.2.
Phase I
Clinical Trial
12.5.2.3.3.
Others
12.5.3. Spain
12.5.3.1.
Spain
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Application
12.5.3.1.1.
Kids
12.5.3.1.2.
Adults
12.5.3.2.
Spain
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.3.2.1.
Healthcare
Facilities
12.5.3.2.2.
Government
Vaccination Campaigns
12.5.3.2.3.
Research
Facilities
12.5.3.2.4.
Others
12.5.3.3.
Spain
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phase
12.5.3.3.1.
Pre-Clinical
12.5.3.3.2.
Phase I
Clinical Trial
12.5.3.3.3.
Others
12.5.4. Germany
12.5.4.1.
Germany
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Application
12.5.4.1.1.
Kids
12.5.4.1.2.
Adults
12.5.4.2.
Germany
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.4.2.1.
Healthcare
Facilities
12.5.4.2.2.
Government
Vaccination Campaigns
12.5.4.2.3.
Research
Facilities
12.5.4.2.4.
Others
12.5.4.3.
Germany
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phase
12.5.4.3.1.
Pre-Clinical
12.5.4.3.2.
Phase I
Clinical Trial
12.5.4.3.3.
Others
12.5.5. Italy
12.5.5.1.
Italy
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Application
12.5.5.1.1.
Kids
12.5.5.1.2.
Adults
12.5.5.2.
Italy
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.5.2.1.
Healthcare
Facilities
12.5.5.2.2.
Government
Vaccination Campaigns
12.5.5.2.3.
Research
Facilities
12.5.5.2.4.
Others
12.5.5.3.
Italy
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phase
12.5.5.3.1.
Pre-Clinical
12.5.5.3.2.
Phase I
Clinical Trial
12.5.5.3.3.
Others
12.5.6. Nordic Countries
12.5.6.1.
Nordic
Countries Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By
Application
12.5.6.1.1.
Kids
12.5.6.1.2.
Adults
12.5.6.2.
Nordic
Countries Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By
End-User
12.5.6.2.1.
Healthcare
Facilities
12.5.6.2.2.
Government
Vaccination Campaigns
12.5.6.2.3.
Research
Facilities
12.5.6.2.4.
Others
12.5.6.3.
Nordic
Countries Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By
Clinical Trial Phase
12.5.6.3.1.
Pre-Clinical
12.5.6.3.2.
Phase I
Clinical Trial
12.5.6.3.3.
Others
12.5.6.4.
Nordic
Countries Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By
Country
12.5.6.4.1.
Denmark
12.5.6.4.2.
Finland
12.5.6.4.3.
Iceland
12.5.6.4.4.
Sweden
12.5.6.4.5.
Norway
12.5.7. Benelux Union
12.5.7.1.
Benelux
Union Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By
Application
12.5.7.1.1.
Kids
12.5.7.1.2.
Adults
12.5.7.2.
Benelux
Union Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.7.2.1.
Healthcare
Facilities
12.5.7.2.2.
Government
Vaccination Campaigns
12.5.7.2.3.
Research
Facilities
12.5.7.2.4.
Others
12.5.7.3.
Benelux
Union Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial Phase
12.5.7.3.1.
Pre-Clinical
12.5.7.3.2.
Phase I
Clinical Trial
12.5.7.3.3.
Others
12.5.7.4.
Benelux
Union Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1.
Belgium
12.5.7.4.2.
The
Netherlands
12.5.7.4.3.
Luxembourg
12.5.8. Rest of Europe
12.5.8.1.
Rest of
Europe Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By
Application
12.5.8.1.1.
Kids
12.5.8.1.2.
Adults
12.5.8.2.
Rest of
Europe Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.8.2.1.
Healthcare
Facilities
12.5.8.2.2.
Government
Vaccination Campaigns
12.5.8.2.3.
Research
Facilities
12.5.8.2.4.
Others
12.5.8.3.
Rest of
Europe Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial Phase
12.5.8.3.1.
Pre-Clinical
12.5.8.3.2.
Phase I
Clinical Trial
12.5.8.3.3.
Others
12.6. Key Segment for Channeling Investments
12.6.1. By Country
12.6.2. By Application
12.6.3. By End-User
12.6.4. By Clinical Trial Phase
13. Asia Pacific Yellow Fever Vaccine Market
Analysis and Forecasts, 2021 - 2029
13.1. Overview
13.1.1. Asia Pacific Yellow Fever Vaccine Market
Revenue (US$ Mn)
13.2. Asia Pacific Yellow Fever Vaccine Market
Revenue (US$ Mn) and Forecasts, By Application
13.2.1. Kids
13.2.2. Adults
13.3. Asia Pacific Yellow Fever Vaccine Market
Revenue (US$ Mn) and Forecasts, By End-User
13.3.1. Healthcare Facilities
13.3.2. Government Vaccination Campaigns
13.3.3. Research Facilities
13.3.4. Others
13.4. Asia Pacific Yellow Fever Vaccine Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
13.4.1. Pre-Clinical
13.4.2. Phase I Clinical Trial
13.4.3. Others
13.5. Asia Pacific Yellow Fever Vaccine Market
Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1.
China
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Application
13.5.1.1.1.
Kids
13.5.1.1.2.
Adults
13.5.1.2.
China
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.1.2.1.
Healthcare
Facilities
13.5.1.2.2.
Government
Vaccination Campaigns
13.5.1.2.3.
Research
Facilities
13.5.1.2.4.
Others
13.5.1.3.
China
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phase
13.5.1.3.1.
Pre-Clinical
13.5.1.3.2.
Phase I
Clinical Trial
13.5.1.3.3.
Others
13.5.2. Japan
13.5.2.1.
Japan
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Application
13.5.2.1.1.
Kids
13.5.2.1.2.
Adults
13.5.2.2.
Japan
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.2.2.1.
Healthcare
Facilities
13.5.2.2.2.
Government
Vaccination Campaigns
13.5.2.2.3.
Research
Facilities
13.5.2.2.4.
Others
13.5.2.3.
Japan
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phase
13.5.2.3.1.
Pre-Clinical
13.5.2.3.2.
Phase I
Clinical Trial
13.5.2.3.3.
Others
13.5.3. India
13.5.3.1.
India
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Application
13.5.3.1.1.
Kids
13.5.3.1.2.
Adults
13.5.3.2.
India
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.3.2.1.
Healthcare
Facilities
13.5.3.2.2.
Government
Vaccination Campaigns
13.5.3.2.3.
Research
Facilities
13.5.3.2.4.
Others
13.5.3.3.
India
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phase
13.5.3.3.1.
Pre-Clinical
13.5.3.3.2.
Phase I
Clinical Trial
13.5.3.3.3.
Others
13.5.4. New Zealand
13.5.4.1.
New
Zealand Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By
Application
13.5.4.1.1.
Kids
13.5.4.1.2.
Adults
13.5.4.2.
New
Zealand Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.4.2.1.
Healthcare
Facilities
13.5.4.2.2.
Government
Vaccination Campaigns
13.5.4.2.3.
Research
Facilities
13.5.4.2.4.
Others
13.5.4.3.
New
Zealand Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial Phase
13.5.4.3.1.
Pre-Clinical
13.5.4.3.2.
Phase I
Clinical Trial
13.5.4.3.3.
Others
13.5.5. Australia
13.5.5.1.
Australia
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Application
13.5.5.1.1.
Kids
13.5.5.1.2.
Adults
13.5.5.2.
Australia
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.5.2.1.
Healthcare
Facilities
13.5.5.2.2.
Government
Vaccination Campaigns
13.5.5.2.3.
Research
Facilities
13.5.5.2.4.
Others
13.5.5.3.
Australia
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phase
13.5.5.3.1.
Pre-Clinical
13.5.5.3.2.
Phase I
Clinical Trial
13.5.5.3.3.
Others
13.5.6. South Korea
13.5.6.1.
South
Korea Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By
Application
13.5.6.1.1.
Kids
13.5.6.1.2.
Adults
13.5.6.2.
South
Korea Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.6.2.1.
Healthcare
Facilities
13.5.6.2.2.
Government
Vaccination Campaigns
13.5.6.2.3.
Research
Facilities
13.5.6.2.4.
Others
13.5.6.3.
South
Korea Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial Phase
13.5.6.3.1.
Pre-Clinical
13.5.6.3.2.
Phase I
Clinical Trial
13.5.6.3.3.
Others
13.5.7. Southeast Asia
13.5.7.1.
Southeast
Asia Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Application
13.5.7.1.1.
Kids
13.5.7.1.2.
Adults
13.5.7.2.
Southeast
Asia Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.7.2.1.
Healthcare
Facilities
13.5.7.2.2.
Government
Vaccination Campaigns
13.5.7.2.3.
Research
Facilities
13.5.7.2.4.
Others
13.5.7.3.
Southeast
Asia Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial Phase
13.5.7.3.1.
Pre-Clinical
13.5.7.3.2.
Phase I
Clinical Trial
13.5.7.3.3.
Others
13.5.7.4.
Southeast
Asia Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1.
Indonesia
13.5.7.4.2.
Thailand
13.5.7.4.3.
Malaysia
13.5.7.4.4.
Singapore
13.5.7.4.5.
Rest of
Southeast Asia
13.5.8. Rest of Asia Pacific
13.5.8.1.
Rest of
Asia Pacific Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By
Application
13.5.8.1.1.
Kids
13.5.8.1.2.
Adults
13.5.8.2.
Rest of
Asia Pacific Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By
End-User
13.5.8.2.1.
Healthcare
Facilities
13.5.8.2.2.
Government
Vaccination Campaigns
13.5.8.2.3.
Research
Facilities
13.5.8.2.4.
Others
13.5.8.3.
Rest of
Asia Pacific Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By
Clinical Trial Phase
13.5.8.3.1.
Pre-Clinical
13.5.8.3.2.
Phase I
Clinical Trial
13.5.8.3.3.
Others
13.6. Key Segment for Channeling Investments
13.6.1. By Country
13.6.2. By Application
13.6.3. By End-User
13.6.4. By Clinical Trial Phase
14. Middle East and Africa Yellow Fever Vaccine
Market Analysis and Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Middle East and Africa Yellow Fever Vaccine
Market Revenue (US$ Mn)
14.2. Middle East and Africa Yellow Fever Vaccine
Market Revenue (US$ Mn) and Forecasts, By Application
14.2.1. Kids
14.2.2. Adults
14.3. Middle East and Africa Yellow Fever Vaccine
Market Revenue (US$ Mn) and Forecasts, By End-User
14.3.1. Healthcare Facilities
14.3.2. Government Vaccination Campaigns
14.3.3. Research Facilities
14.3.4. Others
14.4. Middle East and Africa Yellow Fever Vaccine
Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
14.4.1. Pre-Clinical
14.4.2. Phase I Clinical Trial
14.4.3. Others
14.5. Middle East and Africa Yellow Fever Vaccine
Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1. Saudi Arabia
14.5.1.1.
Saudi
Arabia Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By
Application
14.5.1.1.1.
Kids
14.5.1.1.2.
Adults
14.5.1.2.
Saudi
Arabia Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
14.5.1.2.1.
Healthcare
Facilities
14.5.1.2.2.
Government
Vaccination Campaigns
14.5.1.2.3.
Research
Facilities
14.5.1.2.4.
Others
14.5.1.3.
Saudi
Arabia Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial Phase
14.5.1.3.1.
Pre-Clinical
14.5.1.3.2.
Phase I
Clinical Trial
14.5.1.3.3.
Others
14.5.2. UAE
14.5.2.1.
UAE
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Application
14.5.2.1.1.
Kids
14.5.2.1.2.
Adults
14.5.2.2.
UAE
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
14.5.2.2.1.
Healthcare
Facilities
14.5.2.2.2.
Government
Vaccination Campaigns
14.5.2.2.3.
Research
Facilities
14.5.2.2.4.
Others
14.5.2.3.
UAE Yellow
Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
14.5.2.3.1.
Pre-Clinical
14.5.2.3.2.
Phase I
Clinical Trial
14.5.2.3.3.
Others
14.5.3. Egypt
14.5.3.1.
Egypt
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Application
14.5.3.1.1.
Kids
14.5.3.1.2.
Adults
14.5.3.2.
Egypt
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
14.5.3.2.1.
Healthcare
Facilities
14.5.3.2.2.
Government
Vaccination Campaigns
14.5.3.2.3.
Research
Facilities
14.5.3.2.4.
Others
14.5.3.3.
Egypt
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phase
14.5.3.3.1.
Pre-Clinical
14.5.3.3.2.
Phase I
Clinical Trial
14.5.3.3.3.
Others
14.5.4. Kuwait
14.5.4.1.
Kuwait
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Application
14.5.4.1.1.
Kids
14.5.4.1.2.
Adults
14.5.4.2.
Kuwait
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
14.5.4.2.1.
Healthcare
Facilities
14.5.4.2.2.
Government
Vaccination Campaigns
14.5.4.2.3.
Research
Facilities
14.5.4.2.4.
Others
14.5.4.3.
Kuwait
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phase
14.5.4.3.1.
Pre-Clinical
14.5.4.3.2.
Phase I
Clinical Trial
14.5.4.3.3.
Others
14.5.5. South Africa
14.5.5.1.
South
Africa Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By
Application
14.5.5.1.1.
Kids
14.5.5.1.2.
Adults
14.5.5.2.
South
Africa Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
14.5.5.2.1.
Healthcare
Facilities
14.5.5.2.2.
Government
Vaccination Campaigns
14.5.5.2.3.
Research
Facilities
14.5.5.2.4.
Others
14.5.5.3.
South
Africa Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial Phase
14.5.5.3.1.
Pre-Clinical
14.5.5.3.2.
Phase I
Clinical Trial
14.5.5.3.3.
Others
14.5.6. Rest of Middle East & Africa
14.5.6.1.
Rest of
Middle East & Africa Yellow Fever Vaccine Market Revenue (US$ Mn) and
Forecasts, By Application
14.5.6.1.1.
Kids
14.5.6.1.2.
Adults
14.5.6.2.
Rest of
Middle East & Africa Yellow Fever Vaccine Market Revenue (US$ Mn) and
Forecasts, By End-User
14.5.6.2.1.
Healthcare
Facilities
14.5.6.2.2.
Government
Vaccination Campaigns
14.5.6.2.3.
Research
Facilities
14.5.6.2.4.
Others
14.5.6.3.
Rest of
Middle East & Africa Yellow Fever Vaccine Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial Phase
14.5.6.3.1.
Pre-Clinical
14.5.6.3.2.
Phase I
Clinical Trial
14.5.6.3.3.
Others
14.6. Key Segment for Channeling Investments
14.6.1. By Country
14.6.2. By Application
14.6.3. By End-User
14.6.4. By Clinical Trial Phase
15. Latin America Yellow Fever Vaccine Market
Analysis and Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Latin America Yellow Fever Vaccine Market
Revenue (US$ Mn)
15.2. Latin America Yellow Fever Vaccine Market
Revenue (US$ Mn) and Forecasts, By Application
15.2.1. Kids
15.2.2. Adults
15.3. Latin America Yellow Fever Vaccine Market
Revenue (US$ Mn) and Forecasts, By End-User
15.3.1. Healthcare Facilities
15.3.2. Government Vaccination Campaigns
15.3.3. Research Facilities
15.3.4. Others
15.4. Latin America Yellow Fever Vaccine Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
15.4.1. Pre-Clinical
15.4.2. Phase I Clinical Trial
15.4.3. Others
15.5. Latin America Yellow Fever Vaccine Market
Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1.
Brazil
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Application
15.5.1.1.1.
Kids
15.5.1.1.2.
Adults
15.5.1.2.
Brazil
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
15.5.1.2.1.
Healthcare
Facilities
15.5.1.2.2.
Government
Vaccination Campaigns
15.5.1.2.3.
Research
Facilities
15.5.1.2.4.
Others
15.5.1.3.
Brazil
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phase
15.5.1.3.1.
Pre-Clinical
15.5.1.3.2.
Phase I
Clinical Trial
15.5.1.3.3.
Others
15.5.2. Argentina
15.5.2.1.
Argentina
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Application
15.5.2.1.1.
Kids
15.5.2.1.2.
Adults
15.5.2.2.
Argentina
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By End-User
15.5.2.2.1.
Healthcare
Facilities
15.5.2.2.2.
Government
Vaccination Campaigns
15.5.2.2.3.
Research
Facilities
15.5.2.2.4.
Others
15.5.2.3.
Argentina
Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phase
15.5.2.3.1.
Pre-Clinical
15.5.2.3.2.
Phase I
Clinical Trial
15.5.2.3.3.
Others
15.5.3. Rest of Latin America
15.5.3.1.
Rest of
Latin America Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By
Application
15.5.3.1.1.
Kids
15.5.3.1.2.
Adults
15.5.3.2.
Rest of
Latin America Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By
End-User
15.5.3.2.1.
Healthcare
Facilities
15.5.3.2.2.
Government
Vaccination Campaigns
15.5.3.2.3.
Research
Facilities
15.5.3.2.4.
Others
15.5.3.3.
Rest of
Latin America Yellow Fever Vaccine Market Revenue (US$ Mn) and Forecasts, By
Clinical Trial Phase
15.5.3.3.1.
Pre-Clinical
15.5.3.3.2.
Phase I
Clinical Trial
15.5.3.3.3.
Others
15.6. Key Segment for Channeling Investments
15.6.1. By Country
15.6.2. By Application
15.6.3. By End-User
15.6.4. By Clinical Trial Phase
16. Competitive Benchmarking
16.1. Brand Benchmarking
16.2. Market Share Analysis, 2020
16.3. Global Presence and Growth Strategies
16.3.1. Mergers and Acquisitions
16.3.2. Product Launches
16.3.3. Investments Trends
16.3.4. R&D Initiatives
17. Player Profiles
17.1. Bio-Manguinhos
17.1.1. Company Details
17.1.2. Company Overview
17.1.3. Product Offerings
17.1.4. Key Developments
17.1.5. Financial Analysis
17.1.6. SWOT Analysis
17.1.7. Business Strategies
17.2.
Central
Research Institute Kasauli
17.2.1. Company Details
17.2.2. Company Overview
17.2.3. Product Offerings
17.2.4. Key Developments
17.2.5. Financial Analysis
17.2.6. SWOT Analysis
17.2.7. Business Strategies
17.3.
FSUE
Chumakov
17.3.1. Company Details
17.3.2. Company Overview
17.3.3. Product Offerings
17.3.4. Key Developments
17.3.5. Financial Analysis
17.3.6. SWOT Analysis
17.3.7. Business Strategies
17.4.
iBio
17.4.1. Company Details
17.4.2. Company Overview
17.4.3. Product Offerings
17.4.4. Key Developments
17.4.5. Financial Analysis
17.4.6. SWOT Analysis
17.4.7. Business Strategies
17.5.
Institut
Pasteur de Dakar
17.5.1. Company Details
17.5.2. Company Overview
17.5.3. Product Offerings
17.5.4. Key Developments
17.5.5. Financial Analysis
17.5.6. SWOT Analysis
17.5.7. Business Strategies
17.6.
Sanofi
17.6.1. Company Details
17.6.2. Company Overview
17.6.3. Product Offerings
17.6.4. Key Developments
17.6.5. Financial Analysis
17.6.6. SWOT Analysis
17.6.7. Business Strategies
17.7. Other Market Participants
18. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.